Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
3(50.0%)
Phase 2
2(33.3%)
Early Phase 1
1(16.7%)
6Total
Phase 1(3)
Phase 2(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07399132Early Phase 1Recruiting

A Study of APL-10456-Vaccine

Role: lead

NCT06846554Phase 2Recruiting

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Role: lead

NCT06372717Phase 1Recruiting

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Role: lead

NCT06399757Phase 1Recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Role: lead

NCT06436183Phase 2Completed

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Role: lead

NCT04752371Phase 1Terminated

A Study to Evaluate Camoteskimab in Participants With Still's Disease

Role: lead

All 6 trials loaded